









MTB Selnet September 2023


Maycos Leandro Zapata M
Medical Oncology
IDC Auna – Las Américas
Internal Medicine UdeA










- No comorbidities ECOG 0
- 6 months of left knee pain . The last weeks with weakness










- Core biopsy: Grade 2 mixofibrosarcoma.
- Size In the MRI: 11cmx4.5cm
- Thorax Ct scan: no metastatic disease

Orthopedic oncologist: Upfront surgery



- Core biopsy: Grade 2 mixofibrosarcoma.
- Size In the MRI: 11cmx4.5cm
- Thorax Ct scan: no metastatic disease
- Orthopedic oncologist: Upfront surgery
- Final pathology report: Grade 2 mixofibrosarcoma 10x4.6x4.5cm.
 - Negative bone margin.
 - Anterior margin: 0.6cm.
 - Lateral margin: 0.1cm.
 - Superior margin: 0.1cm
- Adjuvant raditherapy was planed with Gy dose


- Adjuvant Radiotherapy
- VMAT with daily IGRT
- Vol 1: Clinical Postsurgical changes and in the MRI + surgical wedge + presurgical vol:
 - Dosage 50 Gy in 2 Gy fx

- Vol 2: Boost
 - 16 Gy in 2 Gy fx



MLC	Field Weight	Scale	Gantry Rtn [deg]	Coll Rtn [deg]	Couch Rtn [deg]	Wedge	Field X [cm]	X1 [cm]	X2 [cm]	Field Y [cm]	Y1 [cm]	Y2 feml	X [cm]	Y [cm]	Z [cm]
	0.000	IEC61217	0.0	0.0	0.0	None	26.4	-19.8	43344		HILLIH SHOWEN PER GRAN	THE PARTY OF THE P	NAME OF TAXABLE PARTY.	-	
and the same	0.000	IEC61217	0.0	0.0	0.0	None	26.4	-19.8	+6.5	14.0	-7.5	+6.5	0.00	0.80	
Same of	0,000	IEC61217	270.0	0.0	0.0	None	26.4	THE PROPERTY OF THE PARTY OF TH	+6.5	14.0	-7.5	+6.5	0.00	0.80	
	0.000	IEC61217	0.0	0.0	0.0	None	3555555555555555555	-19.8	+6.5	14.0	-7.5	+6.5	0.00	0.80	119
	0.000	IEC61217	270.0	0.0	THE RESERVE OF THE PERSON NAMED IN	THE RESERVE OF THE PARTY OF THE	26,4	-19,8	+6.5	14.0	-7.5	+6.5	0.00	0.80	-3

Total plan 66 Gy



- Qs
- Any concern with margins
- Do you consider RT boots in the close margins
- Do you consider adjuvant chemotherapy





Muchas gracias

Maycos Leandro Zapata M
Oncología Clínica
IDC Auna – Las Américas
Internal Medicine Department UdeA
Maycos.Zapata@udea.edu.co







Diagnosis: Advanced Epithelioid Angiosarcoma of the skull base with multiple bone metastases.

39-years-old Egyptian lady with an unremarkable past medical history.

She was investigated in Egypt for headache, weight loss near 8 kg, and bone pain.

>MRI brain 23.02.2023

Formation 3.6 cm in spheno-occipital region extending to nasal cavity, nasopharynx, clivus, encasing pituitary. Images are not available

**Trans-sphenoidal resection 28.02.2023.

Pathological diagnosis: Epithelioid Angiosarcoma

Strongly positive for vascular markers:CD31, Factor VII. Vascular marker CD34 is focally positive. Erg strongly.


Some epithelial markers:CKAE1 \AE3 ,CAM5.2 are focally positive. EMA is almost negative ,only scattered cells positive.


All the melanoma markers (S100, melanA, HMB45) are negative.

Soon after the surgery headache recurred associated with double vision, and dizziness, bone pain in her hips.


>PET-CT 08.03.2023


Multiple hypermetabolic, predominantly lytic bone lesions in right occipital condyle, right scapula, left humeral head, left 4th rib, few vertebra, pelvis, and hips bilaterally.






- RT to the skull base and sacrum/ sacroiliac joints/ hips/left rib 20Gy 5#
- She was seen in a reference Center in Egypt, started on Denosumab in March 2023 and advised for weekly Paclitaxel and but she moved to Oman by personal reasons.
- Baseline PS-1





d 3 cycles of weekly Paclitaxel from March to May 2023





- We concluded that lesions outside of RT field has grown
- Clinically: ECOG 1, new back pain
- We started her on second line Doxorubicin Ifosfamide Mesna in June 2023
- The pain improved and a new PET-CT after 3 cycles showed partial response. We programmed 3 more cycles.

Before AIM




After AIM x 3



Questions to the board

- -If there is a progression to the second line, should we use antiangiogenic drugs?
- -Should we continue Denosumab?
- -Other treatment options?



50 yo female

Anemia + Myomas

1st symptom: March/23. Back pain (right shoulder- scapula)

Primary care center, rehabilitation, emergency room...

1st diagnosis:


US (15/jun/23): Soft tissue mass with hypodense component


CT-scan (16/jun/23): Soft tissue mass in the peri-scapular region.


- In the meantime, the pt underwent a previously appointed hysterectomy due to myomas.
- The results of the CT-scan are first communicated to the patient at the end of july/23
- She is then refered to Internal medicine for study


- MRI (10/Aug/23): 11x7x10 cm soft tissue lesion in the subscapular área
- Tru-cut biopsy (10/Aug/23) Fusocelular sarcoma G2.
- The patient contacts our center through a Patient's association 31/8/23

RM - 10.08.2023













RM 15.09.2023










CT - 30.08.2023



































Questions:

- NGS of any help?
- Preoperative RT?
- Preoperative systemic treatment?